(Q43041414)

English

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

scientific article published in March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

12 November 2017

2

object named as

Peter Buggisch

0 references

1

object named as

Stefan Zeuzem

1 reference

Europe PubMed Central

12 November 2017

Jean-Pierre Zarski

8

object named as

Jean-Pierre Zarski

0 references

Patrick Marcellin

4

object named as

Patrick Marcellin

1 reference

Europe PubMed Central

12 November 2017

15

object named as

Michael P Manns

1 reference

Europe PubMed Central

12 November 2017

author name string

Peter Buggisch

2

1 reference

Europe PubMed Central

12 November 2017

Kosh Agarwal

3

1 reference

Europe PubMed Central

12 November 2017

Daniel Sereni

5

1 reference

Europe PubMed Central

12 November 2017

Hartwig Klinker

6

1 reference

Europe PubMed Central

12 November 2017

Christophe Moreno

7

1 reference

Europe PubMed Central

12 November 2017

Jean-Pierre Zarski

8

1 reference

Europe PubMed Central

12 November 2017

Yves Horsmans

9

1 reference

Europe PubMed Central

12 November 2017

Hongmei Mo

10

1 reference

Europe PubMed Central

12 November 2017

Sarah Arterburn

11

1 reference

Europe PubMed Central

12 November 2017

Steven Knox

12

1 reference

Europe PubMed Central

12 November 2017

John G McHutchison

14

1 reference

Europe PubMed Central

12 November 2017

Graham R Foster

16

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

1 March 2012

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

55

1 reference

Europe PubMed Central

12 November 2017

749-758

1 reference

Europe PubMed Central

12 November 2017

3

1 reference

Europe PubMed Central

12 November 2017

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

New direct-acting antivirals in the development for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Resistance to direct antiviral agents in patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Hepatitis C virus resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24744

21 January 2018

Identifiers

10.1002/HEP.24744

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43041414&oldid=1590251608"